MacroGenics (NASDAQ:MGNX), headquartered in Rockville, Maryland, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody–based therapies for the treatment of cancer. Since its founding in 2000, the company has leveraged its proprietary Dual-Affinity Re-Targeting (DART) platform to engineer multifunctional antibodies designed to direct the immune system against tumor cells. MacroGenics’ research and development efforts emphasize the creation of next-generation immuno-oncology agents, including bispecific antibodies and antibody–drug conjugates, aimed at improving patient outcomes across a range of solid and hematological malignancies.
At the core of MacroGenics’ pipeline is margetuximab, a monoclonal antibody targeting HER2-positive cancers, which has been evaluated in pivotal clinical studies. Beyond margetuximab, the company is advancing multiple DART-based candidates, such as bispecific T-cell engagers that recruit and activate T cells against tumor-associated antigens. In addition, MacroGenics is exploring antibody–drug conjugates that deliver cytotoxic payloads selectively to cancer cells. The company collaborates with larger pharmaceutical partners and research institutions to accelerate development, licensing, and commercialization of its therapeutic candidates worldwide.
MacroGenics operates globally, maintaining strategic partnerships across the United States, Europe, and Asia to facilitate clinical trials and regulatory approvals. The leadership team is helmed by President and Chief Executive Officer Scott Koenig, who brings extensive industry experience in oncology drug development. The company’s management also includes Chief Scientific Officer Derick Mitnaul and Chief Financial Officer Tony Vastola, each contributing specialized expertise in strategic business planning and scientific innovation. Through its integrated approach to antibody engineering and collaborative alliances, MacroGenics aims to deliver transformative cancer therapies to patients in need.
